Neurological & Psychological Disorders
News on research and diagnostic developments in neuroscience.
C2N Building Case for Alzheimer's Dx as Aducanumab Approval Promises to Impact Testing Space
Premium
FDA's approval of the Biogen anti-amyloid Alzheimer's drug could drive demand for new tests for the disease, including potentially C2N's blood-based assay.
The new reports link variants in CYP2C19 to the safety and efficacy of two drugs, a commonly prescribed antiplatelet drug and an antidepressant.
During an "Investor Day" presentation, company executives presented plans for growing test volumes, increasing market share, and expanding access to underserved populations.
Alzheon, Czech Institute of Organic Chemistry and Biochemistry Partner on Alzheimer's Test
The partners will develop an assay to measure neurotoxic beta amyloid oligomers in human cerebrospinal fluid.
InformedDNA Partners With Gene Therapy Firm Passage Bio on Dementia Genetic Testing
InformedDNA will provide genetic testing to patients diagnosed with frontotemporal dementia to see if they are eligible for certain clinical studies.